{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:34:43Z","timestamp":1787168083849,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pcl.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:03:35Z","timestamp":1637006615000},"page":"185-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevention of Emerging Infections in Children"],"prefix":"10.1016","volume":"69","author":[{"given":"Thanyawee","family":"Puthanakit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvaporn","family":"Anugulruengkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watsamon","family":"Jantarabenjakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2021.08.006_bib1","author":"World Health Organization"},{"issue":"1","key":"10.1016\/j.pcl.2021.08.006_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/cid\/cis295","article-title":"H5N1 avian influenza in children","volume":"55","author":"Oner","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.08.006_bib3","doi-asserted-by":"crossref","first-page":"e0161925","DOI":"10.1371\/journal.pone.0161925","article-title":"Differences in the Epidemiology of Childhood Infections with Avian Influenza A H7N9 and H5N1 Viruses","volume":"11","author":"Sha","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa044021","article-title":"Probable person-to-person transmission of avian influenza A (H5N1)","volume":"352","author":"Ungchusak","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.pcl.2021.08.006_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14760584.2013.811178","article-title":"Clinical vaccine development for H5N1 influenza","volume":"12","author":"Clegg","year":"2013","journal-title":"Expert Rev Vaccin"},{"issue":"9587","key":"10.1016\/j.pcl.2021.08.006_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvant rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcl.2021.08.006_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/590913","article-title":"An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults","volume":"198","author":"Levie","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"12","key":"10.1016\/j.pcl.2021.08.006_bib11","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.pcl.2021.08.006_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/jiu548","article-title":"AS03B-adjuvanted H5N1 influenza vaccine in children 6\u00a0months through 17 years of age: a phase 2\/3 randomized, placebo-controlled, observer-blinded trial","volume":"211","author":"Kosalaraksa","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.pcl.2021.08.006_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4161\/hv.26495","article-title":"A\u00a0phase II study of an investigational tetravalent influenza vaccine formulation combining MF59\u00ae: adjuvanted, pre-pandemic, A\/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults","volume":"10","author":"Herbinger","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.pcl.2021.08.006_bib14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pcl.2021.08.006_bib16","doi-asserted-by":"crossref","first-page":"607333","DOI":"10.3389\/fimmu.2020.607333","article-title":"Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses","volume":"11","author":"Kerstetter","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.pcl.2021.08.006_bib17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-Adjuvanted Influenza Vaccines in Children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.phrp.2015.08.006","article-title":"Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015","volume":"6","year":"2015","journal-title":"Osong Public Health Res Perspect"},{"issue":"9","key":"10.1016\/j.pcl.2021.08.006_bib19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/INF.0000000000000325","article-title":"Middle East respiratory syndrome coronavirus disease in children","volume":"33","author":"Memish","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5409\/wjcp.v5.i4.391","article-title":"Middle East respiratory syndrome coronavirus disease is rare in children: An update from Saudi Arabia","volume":"5","author":"Al-Tawfiq","year":"2016","journal-title":"World J Clin Pediatr"},{"issue":"12","key":"10.1016\/j.pcl.2021.08.006_bib21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3201\/eid2112.151132","article-title":"Asymptomatic MERS-CoV Infection in Humans Possibly Linked to Infected Dromedaries Imported from Oman to United Arab Emirates, May 2015","volume":"21","author":"Al Hammadi","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.pcl.2021.08.006_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3201\/eid2201.151340","article-title":"Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014","volume":"22","author":"Alraddadi","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.pcl.2021.08.006_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1306742","article-title":"Hospital outbreak of Middle East respiratory syndrome coronavirus","volume":"369","author":"Assiri","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.pcl.2021.08.006_bib25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1303729","article-title":"Family cluster of Middle East respiratory syndrome coronavirus infections","volume":"368","author":"Memish","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib26","doi-asserted-by":"crossref","first-page":"e01450-14","DOI":"10.1128\/mBio.01450-14","article-title":"Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient","volume":"5","author":"Azhar","year":"2014","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.pcl.2021.08.006_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.micinf.2014.05.002","article-title":"Calling for rapid development of a safe and effective MERS vaccine","volume":"16","author":"Hotez","year":"2014","journal-title":"Microbes Infect"},{"key":"10.1016\/j.pcl.2021.08.006_bib28","series-title":"WHO MERS global summary and Assessment of risk","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.pcl.2021.08.006_bib29","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.tmaid.2019.101520","article-title":"MERS-CoV as an emerging respiratory illness: A review of prevention methods","volume":"32","author":"Baharoon","year":"2019","journal-title":"Trav Med Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2021.08.006_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11250-010-9529-y","article-title":"Non-genetic factors influencing reproductive traits and calving weight in Saudi camels","volume":"42","author":"Almutairi","year":"2010","journal-title":"Trop Anim Health Prod"},{"issue":"1","key":"10.1016\/j.pcl.2021.08.006_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhin.2018.09.005","article-title":"Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers","volume":"101","author":"Park","year":"2019","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.pcl.2021.08.006_bib32","author":"World Health Organization"},{"key":"10.1016\/j.pcl.2021.08.006_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.onehlt.2017.03.001","article-title":"Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus","volume":"3","author":"Vergara-Alert","year":"2017","journal-title":"One Health"},{"issue":"14","key":"10.1016\/j.pcl.2021.08.006_bib35","doi-asserted-by":"crossref","first-page":"eaan5393","DOI":"10.1126\/sciimmunol.aan5393","article-title":"Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses","volume":"2","author":"Zhao","year":"2017","journal-title":"Sci Immunol"},{"issue":"9","key":"10.1016\/j.pcl.2021.08.006_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.pcl.2021.08.006_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.pcl.2021.08.006_bib38","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pcl.2021.08.006_bib39","author":"World Health Organization"},{"key":"10.1016\/j.pcl.2021.08.006_bib40","author":"World Health Organization"},{"issue":"7446","key":"10.1016\/j.pcl.2021.08.006_bib41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.pcl.2021.08.006_bib42","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2021.08.006_bib43","author":"World Health Organization"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib44","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.idc.2019.08.006","article-title":"Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention","volume":"33","author":"Vairo","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.pcl.2021.08.006_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.actatropica.2018.09.003","article-title":"A\u00a0scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control","volume":"188","author":"Silva","year":"2018","journal-title":"Acta Trop"},{"key":"10.1016\/j.pcl.2021.08.006_bib47","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fcimb.2017.00336","article-title":"Prevention and Control Strategies to Counter Dengue Virus Infection","volume":"7","author":"Rather","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.pcl.2021.08.006_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13071-015-0959-2","article-title":"Paratransgenesis: a promising new strategy for mosquito vector control","volume":"8","author":"Wilke","year":"2015","journal-title":"Parasit Vectors"},{"issue":"13","key":"10.1016\/j.pcl.2021.08.006_bib49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2021.08.006_bib51","author":"World Health Organization"},{"issue":"35","key":"10.1016\/j.pcl.2021.08.006_bib52","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018 - Recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.pcl.2021.08.006_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clp.2021.03.006","article-title":"Ebola, Dengue, Chikungunya, and Zika Infections in Neonates and Infants","volume":"48","author":"de St Maurice","year":"2021","journal-title":"Clin Perinatol"},{"issue":"4","key":"10.1016\/j.pcl.2021.08.006_bib54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1473-3099(20)30767-2","article-title":"Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study","volume":"21","author":"Coronel-Mart\u00cdnez","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pcl.2021.08.006_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coviro.2020.09.004","article-title":"Dengue vaccine development by the year 2020: challenges and prospects","volume":"43","author":"Wilder-Smith","year":"2020","journal-title":"Curr Opin Virol"},{"issue":"6","key":"10.1016\/j.pcl.2021.08.006_bib56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14760584.2020.1775076","article-title":"Dengue vaccine: a key for prevention","volume":"19","author":"Thisyakorn","year":"2020","journal-title":"Expert Rev Vaccin"},{"issue":"10234","key":"10.1016\/j.pcl.2021.08.006_bib57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcl.2021.08.006_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0035-9203(57)90022-6","article-title":"An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-1953; an additional note on Chikungunya virus isolations and serum antibodies","volume":"51","author":"Mason","year":"1957","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.pcl.2021.08.006_bib59","series-title":"Mandell, Douglas, and Bennett's Principles and practice of infectious diseases","first-page":"1997","article-title":"Alphaviruses (Chikungunya, Eastern Equine Encephalitis)","author":"Markoff","year":"2020"},{"key":"10.1016\/j.pcl.2021.08.006_bib62","series-title":"Red Book: 2018 report of the Committee on infectious diseases","first-page":"271","article-title":"Chikungunya","year":"2018"},{"issue":"7","key":"10.1016\/j.pcl.2021.08.006_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/PEC.0000000000001529","article-title":"Chikungunya in Children: A Clinical Review","volume":"34","author":"Ward","year":"2018","journal-title":"Pediatr Emerg Care"},{"issue":"3","key":"10.1016\/j.pcl.2021.08.006_bib65","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.pcl.2021.08.006_bib66","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"Gorchakov","year":"2012","journal-title":"J\u00a0Virol"},{"issue":"5","key":"10.1016\/j.pcl.2021.08.006_bib67","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"Halleng\u00e4rd","year":"2014","journal-title":"J\u00a0Virol"},{"issue":"10","key":"10.1016\/j.pcl.2021.08.006_bib69","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A\u00a0Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"9959","key":"10.1016\/j.pcl.2021.08.006_bib70","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.pcl.2021.08.006_bib71","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pcl.2021.08.006_bib72","first-page":"1229","article-title":"Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA","volume":"159","author":"Kuhn","year":"2014","journal-title":"Arch Virol"},{"issue":"10174","key":"10.1016\/j.pcl.2021.08.006_bib73","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2021.08.006_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2352-4642(18)30409-7","article-title":"Children's needs in an Ebola virus disease outbreak","volume":"3","author":"The Lancet Child Adolescent Health","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2021.08.006_bib75","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/514318","article-title":"Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epid\u00e9mies \u00e0 Kikwit","volume":"179","author":"Rowe","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"9768","key":"10.1016\/j.pcl.2021.08.006_bib76","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2021.08.006_bib77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","article-title":"Clinical presentation of patients with Ebola virus disease in Conakry, Guinea","volume":"372","author":"Bah","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10172","key":"10.1016\/j.pcl.2021.08.006_bib79","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(19)30242-9","article-title":"The evolution of supportive care for Ebola virus disease","volume":"393","author":"Lamontagne","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.pcl.2021.08.006_bib80","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"Schieffelin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.pcl.2021.08.006_bib81","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A\u00a0Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2021.08.006_bib82","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1086\/514286","article-title":"Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure","volume":"179","author":"Roels","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.pcl.2021.08.006_bib83","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1086\/520545","article-title":"Assessment of the risk of Ebola virus transmission from bodily fluids and fomites","volume":"196","author":"Bausch","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.pcl.2021.08.006_bib84","series-title":"Principles and practice of pediatric infectious diseases","first-page":"1190","article-title":"Filoviruses and Arenaviruses","author":"Anderson","year":"2017"},{"issue":"10068","key":"10.1016\/j.pcl.2021.08.006_bib85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"suppl_1","key":"10.1016\/j.pcl.2021.08.006_bib86","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jiy061","article-title":"Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola","volume":"217","author":"Conteh","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"12","key":"10.1016\/j.pcl.2021.08.006_bib87","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report [published correction appears in Lancet Infect Dis. 2017 Dec;17 (12 ):1232]","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2021.08.006_bib88","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:08Z","timestamp":1758475568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395521001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0031395521001395"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2021.08.006","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of Emerging Infections in Children","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}